---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012812"
form_type: "8-K"
ticker: "MBOT"
cik: "0000883975"
company_name: "Microbot Medical Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:57:03.448465+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emory performs first robotic PAE and Y-90 mapping using Microbot's LIBERTY System

## Summary
- World's first robotic prostate artery embolization (PAE) for BPH performed with LIBERTY at Emory.
- First robotic Y-90 radioembolization mapping for liver cancer completed using the same system.
- LIBERTY is FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
- Limited Market Release started November 2025; Full Market Release planned for April 2026 at SIR conference.
- BPH affects approximately 40 million men in the U.S.; LIBERTY aims to become standard of care for PAE.

## SEC filing metadata
- accession: 0001493152-26-012812
- form_type: 8-K
- ticker: MBOT
- cik: 0000883975
- company_name: Microbot Medical Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/883975/000149315226012812/0001493152-26-012812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/883975/000149315226012812/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012812
- JSON: https://secwatch.observer/filing/0001493152-26-012812.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012812.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.